

## PEOPLE

Joseph B. Bolen has been appointed head of Hoechst Marion Roussel's (Bridge-water, NJ) oncology disease group. Dr. Bolen comes to Hoechst Marion Roussel from the DNAX Research Institute, where he was director of the department of cellular signaling.



CpG ImmunoPharmaceuticals (Wellesley, MA) has named Robert L. Bratzler president and CEO. Dr. Bratzler joins the company from Encore Pharmaceuticals, where he was chairman and cofounder.

Celera Genomics Corp. (Rockville, MD) has named Samuel Broder executive vice president and chief medical officer, and L. Stevenson Parker as vice president of administration and legal affairs. Dr. Broder is the former director of the National Cancer Institute, and most recently was senior vice president for R&D of IVAX Corp. Mr. Parker has been a partner at Arnold & Porter since 1990.

Sequenom (San Diego, CA) has announced that Charles R. Cantor, professor of biomedical engineering and pharmacology at Boston University, has joined the company as its chief scientific officer. Dr. Cantor was previously a member of Sequenom's scientific advisory board.

Hugh Collum has been appointed as chairman and a director of Chiroscience Group (London), succeeding Lord Henry Chilver. Mr. Collum is currently executive vice president and chief financial officer of SmithKline Beecham. Chiroscience also announced that Robert Jackson has been promoted to executive director, R&D, broadening his existing responsibilities.

Rigel (Sunnyvale, CA) has announced that Brian Cunningham has joined the company in the newly created position of chief operating officer. Mr. Cunningham was previously a partner and head of the life sciences and healthcare practices of Cooley Godward LLP.



R. James Danehy has been elected vice chairman of the board of directors of Oncor (Gaithersburg, MD), and it is expected that he will be named chief executive officer at the end of the year. Mr. Danehy is currently president and CEO of Centocor Diagnostics.

The US Federal Bureau of Investigation has named Arthur Eisenberg chairman of its

DNA advisory board. Dr. Eisenberg is associate professor of pathology at the University of North Texas Health Science Center (Fort Worth, TX). He succeeds Joshua Lederberg of Rockefeller University, and will serve as chairman through March 2000.

British Biotech (Oxford, UK) has appointed Elliot Goldstein chief executive officer. Dr. Goldstein comes to the company from SmithKline Beecham, where he is senior vice president and director of worldwide strategic product development. He succeeds Keith McCullagh, who retired from the board in September. Dr. Goldstein will also take over the role of commercial director from Pam Kirby.

ChiRex (Stamford, CT) has named Michael A. Griffith chairman of the board and CEO. Mr. Griffith has been with ChiRex since 1996, as a member of the office of the chief executive, chief financial officer, and as a member of the board of directors. ChiRex also announced that Elizabeth M. Greetham has resigned her positions as chairman of the board and as a director.

LXR Biotechnology (Richmond, CA) has appointed Paul J. Hastings to the position of

president and CEO and to the board of directors. He succeeds interim CEO G. Kirk Raab, who will remain with LXR as chairman. Mr. Hastings was most recently president of Genzyme Therapeutics.

BioMarin Pharmaceutical (Novato, CA) has named Stuart J. Sweidler vice president, scientific and clinical affairs, and Raymond W. Anderson vice president, finance and administration and CFO. In addition, the company also announced the appointment of Emil D. Kakkis as president of its newly created division, BioMarin Genetics.


Calydon (Sunnyvale, CA) has named Robert H. Tidwell vice president of business development. Mr. Tidwell joins Calydon from Pharmagenesis, where he served as vice president and general manager.

Lutz Weber has joined Morphochem AG (Martinsried, Germany) as vice president, science and technology. Prior to joining Morphochem, Dr. Weber was vice director at Hoffmann-La Roche, responsible for combinatorial chemistry and pharmaceutical projects.

## Early Detection of Neurotoxicity

### Brain Histology Services:

- Discover Neurotoxicity Rapidly
- Accelerate Drug Development
- Assess Neuroprotection
- Reduce Behavioral Tests



Silver Degeneration Stain Specialists



MultiBrain Technology™

yields:

- high throughput
- uniform staining



(Section from MultiBrain Block)

Innovative Technology  
for Leaders in  
Drug Development

## NEUROSCIENCE ASSOCIATES

<http://members.aol.com/nervdoc> [nervdoc@aol.com](mailto:nervdoc@aol.com)

10915 Lake Ridge Dr. Knoxville, TN 800 972-3401